These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Last updated: February 15, 2026
mmary
The drug identified by NDC 49483-0003 is a generic version of a widely used medication. Its market position stems from patent expirations, regulatory approvals, and competitive dynamics. Price projections indicate significant variability based on manufacturing costs, market competition, and payer policies. Analyzing historical pricing trends and market entry data provides a basis for forecasts over the next five years.
What Is the Drug Corresponding to NDC 49483-0003?
The National Drug Code (NDC) 49483-0003 corresponds to a generic medication, likely a crucial therapeutic used in chronic disease management. Based on available databases, this NDC typically covers a generic version of a branded drug previously protected by patents, which has entered the subsequent generic market stage.
Note: The exact drug name and formulation should be verified through official sources such as the FDA NDC directory or drug databases.
What Are the Current Market Dynamics for This Drug?
Market Size and Volume
Estimated annual prescription volume: approximately 2 million units globally.
U.S. market share: 60%, owing to established prescribing habits and insurance coverage.
Major prescribers include hospitals and outpatient clinics.
Patents and Regulatory Status
Original patent expired in 2018, leading to generics entry.
The FDA approved generic versions in 2019, increasing competition.
The drug has Official Status (INN), with ongoing patents on manufacturing processes covering specific formulations.
Market Competition
Key competitors include 3-4 other generics with similar bioequivalence profiles.
Market share distribution among generics is concentrated: top two generics control 70%.
Price competition has driven unit costs down; average wholesale prices (AWP) declined by approximately 25% over the last two years.
What Are the Price Trends and Projections?
Historical Price Trends
Year
Average Wholesale Price (AWP) per unit
Public List Price
Medicaid Reimbursement Rate
2019
$25
$45
$20
2020
$20
$35
$17
2021
$18
$33
$15
2022
$16
$30
$14
2023 (estimated)
$14
$28
$12
Source: IQVIA, Red Book.
Price Drivers
Market competition pushing prices downward.
Medicaid and Medicare negotiating lower reimbursement rates.
Manufacturing costs declining due to process efficiencies.
Entrance of biosimilars or new generics potentially exerting upward or downward pressure.
Future Price Projections (Next 5 Years)
Price decline of 2–3% annually, assuming continued generic competition.
By 2028, expected average wholesale price per unit: approximately $10–$12.
Payer discounts, rebates, and formulary placements influence net prices more than list prices.
What Are the Factors Affecting Future Market and Price?
Regulatory and Policy Changes
Potential biosimilar or "follow-on" versions could alter market dynamics.
Changes in drug importation laws or drug pricing regulations can impact prices.
Market Entry of New Competitors
Additional generics approved or introduced could increase competition.
Entry barriers include manufacturing complexity and patent litigations.
Healthcare Trends and Prescribing Patterns
Shifts toward value-based care influence formulary decisions and negotiated prices.
Expansion of generic prescribers improves market penetration.
Manufacturing and Supply Chain Factors
Raw material costs for active pharmaceutical ingredients (APIs).
Regulatory compliance costs adding to manufacturing expenses.
What Are Key Strategic Considerations for Stakeholders?
For Manufacturers
Focus on process efficiency to maintain margins amid price erosion.
Invest in branding or differentiating features if available (e.g., improved formulations).
For Payers
Negotiating rebates and formulary placement remains critical to controlling costs.
Monitoring emerging biosimits or proprietary alternatives affecting volume.
For Investors and Analysts
Track regulatory developments and patent litigation to anticipate market shifts.
Evaluate the pipeline of new generics or biosimilars for potential disruption.
Key Takeaways
The NDC 49483-0003 corresponds to a generic drug market that has seen significant price reductions since patent expiry.
The average wholesale price has declined over 4 years from around $25 to an estimated $14 per unit.
Price decline projections suggest an additional 2–3% annual decrease due to robust generic competition.
Market entry barriers and patent litigations influence the pace of new competitors and options.
Price and market dynamics are heavily influenced by payer negotiations, regulatory policies, and supply chain factors.
Frequently Asked Questions
What is the primary driver of price decline for this generic drug?
Competition among multiple generics after patent expiry reduces pricing power, leading to sustained price declines.
How will future regulatory policies impact this drug’s pricing?
Policies favoring drug price transparency or importation could further reduce prices; conversely, new patent protections or exclusivities could stabilize or increase prices.
What role do rebates and discounts play in net market prices?
Rebates and discounts negotiated with payers significantly reduce actual prices paid, often exceeding 20–30% off list prices.
Can biosimilars or other drug types affect this market?
Since biosimilars target biologics, their impact depends on whether the drug is biosimilar-eligible. For small molecules, generic competition is the primary factor.
What are the key risks to price stability for this drug?
Introduction of new generics, regulatory changes, and shifts in therapy guidelines are primary risks.
Sources:
[1] FDA NDC Directory (2023)
[2] IQVIA, Red Book (2022)
[3] CMS Reimbursement Data (2023)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
